Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL

NCT05931263 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT05931263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05931263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2023
Completion date
February 29, 2028
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed peripheral t-cell lymphoma